Dr Axel Gille

Dr Axel Gille

Dr. Axel Gille is Managing Director of Aurora Europe GmbH and Aurora Deutschland GmbH. He joined the company 2018 and is responsible for the strategic direction with the goal of establishing Aurora as the clear market leader in all European countries where medical cannabis is licensed. A chemist by education, he spent more than 20 years in management consulting at the global advisory firms McKinsey and KMPG. There he advanced ambitious strategic and overarching operational goals and gained extensive international management experience.

Carola Perez

Carola Perez

Carola Pérez has a degree in Audiovisual Communication, a field to which she has dedicated most of her professional life. She currently chairs the Spanish Medicinal Cannabis Observatory and is the founder of the association of therapeutic users dosemociones, where she advises, supports all those patients who use cannabis for medicinal purposes and works for the regulation of therapeutic cannabis.

Piernicola Pedicini MEP

Piernicola Pedicini MEP

Piernicola Pedicini is an Italian politician and member of the European Parliament since 2014. He is a member of the Committee on Committee on Economic and Monetary Affairs, and a substitute member of the Committee on the Environment, Public Health and Food Safety. He was one of the co-sponsors of the Resolution on the use of cannabis for medicinal purposes voted in the European Parliament in February 2019.

Cristina Romero de Alba

Cristina Romero de Alba

Cristina Romero de Alba is a Partner at LOYRA Abogados y Asesores since April 2011. She leads the international practice area of Loyra. Cristina regularly advises operators and investors in licensing, M&A and general regulatory and compliance procedures in regulated industries including cannabis for medicinal, cosmetics and food use.

José Antonio de la Puente

José Antonio de la Puente

José Antonio de la Puente has been the CEO of Alcaliber S.A.U. since 2004. Alcaliber is a leading independent supplier of active pharmaceutical ingredients for the international pharmaceutical industry. He is also the CEO of Linneo Health since October 2018, a Spanish Company founded for the activities of cultivation, production, manufacturing, import, export, distribution and trade of cannabis and cannabis products for medical and scientific purposes, as well as research linked to the development of these activities.

Dr Viola Brugnatelli

Dr Viola Brugnatelli

Viola Brugnatelli is the scientific director of Cannabiscienza, an e-learning academy for Italian health care professionals on Medical Cannabis and the Endocannabinoid System. Dr Brugnatelli is a lecturer on Medical Cannabis at the University of Padua (Italy) as well as a researcher at the Department of Neuroscience within the same institute. Since 2012 she is an active member of IACM and ICRS, and was recently nominated IACM Italian Ambassador. Dr Brugnatelli advocates for patient-inspired clinical research and collaborates with non-for-profit organisations. In 2018 Brugnatelli co-founded a non-for-profit which lobbies for women equality in the European cannabis sphere.

Stephen Murphy

Stephen Murphy

Stephen is Co-Founder and Managing Director of Prohibition Partners, the leading source of intelligence and insights into the European cannabis industry and Co-Founder of Cannabis Europa, Europe’s premier medical cannabis conference. Stephen is also Co-Founder & Director of NOBL, a global leader in cannabis data, events and media, managing a portfolio of some of the best-known brands in the industry. With a background in technology, digital media and corporate finance, Stephen works with investors, entrepreneurs and regulators to identify, qualify and maximise the opportunities in this emerging frontier.

Dr Bruno Maia

Dr Bruno Maia

Bruno Maia is a Portuguese MD, specialist in Neurology and Critical Care Medicine. He works in the acute care of stroke patients and is responsible for the Neurovascular Ultrasonographic Laboratory at Centro Hospitalar de Lisboa Central (terciary hospital located in Lisbon).

Paul Gurney

Paul Gurney

Paul Gurney is a Managing Director at BMO Capital Markets in London, UK, leading BMO’s coverage of large institutional equity clients in Europe and Asia Pacific. Paul has 15 years of capital markets experience, researching companies, syndicating transactions, structuring deals, and providing value-added advice to institutional and corporate clients across multiple sectors. Paul has been closely involved in the sector in Europe ever since, helping raise US$153m for Tilray, the first ever NASDAQ listed cannabis company, and the third best performing IPO in the US in 2018. Paul spearheads BMO’s investment efforts for cannabis companies in Europe, and Australia, introducing investors to sector heavyweights like Aphria, Aurora, Canopy Growth and Tilray, while actively developing the next generation of pre-IPO cannabis companies.

Guillermo Moreno Sanz

Guillermo Moreno Sanz

Dr. Moreno-Sanz has authored 25+ scientific articles and 3 patents describing the role of the endocannabinoid system on pain perception. He gained broad international experience with long-term fellowships in the Netherlands, Italy and the US, where he has developed most of his career at the University of California, Irvine, working with Prof. Daniele Piomelli, where he discovered a new class of cannabinoid analgesics devoid of unwanted psychoactivity. He participated in the elaboration of the 2017 report “The Health Effects of Cannabis and Cannabinoids” by the National Academies of Sciences. He then relocated to Spain and founded Abagune Research, a privately-owned company that provides scientific advise, research solutions and product development services to regulators, disseminators and operators within the international cannabis industry.

Dr Veronica Codesido Sampedro

Dr Veronica Codesido Sampedro

Dr. Verónica Codesido is the Manager of Breeding and Cultivation Department of Phytoplant Research S.L, the first authorized Spanish company to work with Cannabis sativa for research purposes. She is Doctor in Biology and have many years of experience as a breeder of many kinds of species. She developed her postdoc on in vitro culture and molecular biology of forest species and, nowadays, she is using all the learnt techniques to improve and accelerate the Cannabis breeding program of the company.

Dr	Janosch Kratz

Dr Janosch Kratz

Born in Germany and graduated in Medicine at Sant Pau Hospital in Barcelona, Dr Janosch Kratz became a member of the Kalapa Clinic medical team in May 2016. Today, Janosch is living between Germany and Spain doing his specialist training in Berlin and offering advice on Cannabinoid therapies for Kalapa Clinic. He is responsible for the development of the Kalapa project, coordinates the training of health care professionals and the research of new indications for medical cannabis use. He also offers consulting for the European market regarding innovative administration routes, quality control and product improvement.

Salvador Garcia-Ruiz

Salvador Garcia-Ruiz

Salvador Garcia-Ruiz is the Managing Director of Aurora Medicine Spain since 2019. His experience includes consulting, banking, education and, more recently, media.

Hannah Deacon

Hannah Deacon

Hannah Deacon is the mother of Alfie Dingley, a six-year-old boy with a rare form of epilepsy. When Hannah and Alfie moved to Holland for five months to access medicine containing THC, Alfie's condition improved dramatically, after which Hannah became the first person to legally enter UK with cannabis oil to help her son in June 2018.

Prof. José Javier Fernandez Ruiz

Prof. José Javier Fernandez Ruiz

José Javier Fernández-Ruiz is Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine at the Complutense University of Madrid. He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University. The main activity of this group is the study of the therapeutic potential of cannabinoids in several neurological diseases, mainly neurodegenerative, activity addressed to the design, synthesis and biological characterization of novel cannabinoids with neuroprotective profile, and to test their therapeutic efficacy at preclinical and clinical levels. Professor Fernandez is also a member of the Editorial Board in the British Journal of Pharmacology.

Luis de Palacio

Luis de Palacio

Luis de Palacio is a pharmacist and lawyer. He owns a pharmacy in Pozuelo de Alarcón, and is President of FEFE, the Spanish Federation of Pharmacies. Mr de Palacio is also a member of the College of Pharmacists in Madrid, where he participates in reviewing functions in the Resources Commission.

Beau Epperly

Beau Epperly

Beau Epperly advises startup-business clients in all aspects of the startup cycle; from formation to exit. He guides mature companies through complex securities and tax regulatory matters. He and his team have led a variety of funding deals for startups and recapitalization funding for existing businesses.

James O’Dowd

James O’Dowd

James established the European Alliance for Medicinal Cannabis (EAMC) in February 2019 with the central aim of promoting a sensible policy towards medicinal cannabis in the EU27. Prior to establishing EAMC, in his capacity as Managing Director of TPA Research, James advised several firms on the regulatory landscape governing medicinal cannabis in several European markets, no two of which were alike. Prior to joining TPA as a government affairs analyst in 2012, James worked in the European Parliament as a political adviser and head of research to Vice-Chairman of the European Conservatives and Reformists Group, Geoffrey Van Orden MEP.

José Luis Adrio

José Luis Adrio

Dr. José Luis Adrio holds a Ph.D. in Pharmacy from the University of Santiago de Compostela and an Organization & Management of Technological Innovation program from the Polytechnic University of Madrid. He has been a postdoctoral researcher at the Department of Biology at MIT, Cambridge, EE.UU and has developed his profesional activity in several biotech companies such as Antibióticos de León, Puleva Biotech, Neuron Biopharma, Neol Bio and Evolgene. Currently he is the R&D director at ADL Biopharma.

Expert in the development of microbial biotechnology processes from laboratory to pilot scale, molecular biology techniques and metabolic engineering. He has also deep knowledge about development programs of microbial strains as well as management of R&D projects.

João Gama

João Gama

João Gama is lawyer and policy advisor based in Lisbon. As a partner at Gama Glória, a law firm based in Lisbon, and a senior advisor at the Albright Stonebridge Group, a consulting firm based in Washington D.C., he has been focusing on disruptive, innovative and frontier business models, in the technology, transportation, and healthcare sectors, including cannabis. João is affiliated with the Law School of the Portuguese Catholic University, where he regularly teaches on tax and regulatory issues, having recently taught the first course on the Regulation of Medical Cannabis in the country. João is a member of the Business Ethics Committee of the Portuguese Pharma Association and served as a member of the Portuguese Government as Secretary of State for Local Government and as a political advisor to the President.

  • 1
  • 2